Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL
Charles Herbaux, MD, MSc, University Hospital of Lille, Lille, France, gives an overview of the findings of the primary analysis of a Phase II trial of atezolizumab plus venetoclax and obinutuzumab for the treatment of patients with relapsed/refractory follicular lymphoma and marginal zone lymphoma (MZL). 58 patients with follicular lymphoma were enrolled in the trial with a median follow-up of 14.5 months, and 20 patients with MZL were enrolled in the trial with a median follow-up of 11.9 months. The follicular lymphoma cohort reported an overall response rate (ORR) of 53.6% and the MZL cohort reported an ORR of 66.76%. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Смотрите видео Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL онлайн без регистрации, длительностью часов минут секунд в хорошем качестве. Это видео добавил пользователь VJHemOnc – Video Journal of Hematology & HemOnc 11 Июнь 2021, не забудьте поделиться им ссылкой с друзьями и знакомыми, на нашем сайте его посмотрели 159 раз и оно понравилось 0 людям.